Conference Coverage

Prediabetes is linked independently to myocardial infarction


 

FROM ENDO 2022

Worsening prediabetes should be addressed

“Prediabetes is not treated with medication, at least initially,” Dr. Thota explained. Rather, patients are educated about important lifestyle changes, such as diet and physical activity, that can reverse the diagnosis. However, patients who remain on a path of worsening hyperglycemia are candidates for more intensive lifestyle intervention and might be considered selectively for metformin.

“Early recognition of prediabetes through screening is important,” Dr. Thota emphasized. The benefit for preventing patients from progressing to diabetes is well recognized, but these data provide the basis for incentivizing lifestyle changes in patients with prediabetes by telling them that it can reduce their risk for MI.

Dr. Deepak L. Bhatt, Brigham and Women’s Hospital Heart & Vascular Center, Boston

Dr. Deepak L. Bhatt

These data have an important message, but they are not surprising, according to Deepak L. Bhatt, MD, executive director, interventional cardiovascular programs, Brigham and Women’s Hospital Heart & Vascular Center, Boston.

“In fact, in daily practice we see a substantial percentage of patients with MI who have prediabetes that had not been previously recognized or formally diagnosed,” Dr. Bhatt said in an interview.

“Identifying these patients – preferably prior to coming in with cardiovascular complications – is important both to reduce cardiovascular risk but also to try and prevent progression at diabetes,” he added.

Dr. Bhatt went on to say that this large analysis, confirming that prediabetes is independently associated with MI, should prompt clinicians to screen patients rigorously for this condition.

“At a minimum, such patients would be candidates for intensive lifestyle modification aimed at weight loss and treatment of frequent coexistent conditions, such as hypertension and dyslipidemia,” Dr. Bhatt said.

Dr. Thota reports no potential conflicts of interest. Dr. Bhatt has financial relationships with more than 30 pharmaceutical companies, many of which make products relevant to the management of diabetes and cardiovascular disease.

Pages

Recommended Reading

LDL lowering to specific targets may offset risk from high Lp(a)
MDedge Internal Medicine
ADA prioritizes heart failure in patients with diabetes
MDedge Internal Medicine
Omega-3 supplement sweet spot found for BP reduction
MDedge Internal Medicine
Will tirzepatide slow kidney function decline in type 2 diabetes?
MDedge Internal Medicine
‘Sit less, move more’ to reduce stroke risk
MDedge Internal Medicine
CTO PCI success rates rising, with blip during COVID-19, registry shows
MDedge Internal Medicine
‘Genetic’ height linked to peripheral neuropathy and certain skin and bone infections
MDedge Internal Medicine
ADA updates on finerenone, SGLT2 inhibitors, and race-based eGFR
MDedge Internal Medicine
Jury still out on cardiovascular safety of testosterone
MDedge Internal Medicine
SGLT2 inhibitors cut AFib risk in real-word analysis
MDedge Internal Medicine